TABLE 3.
Summary of endpoints after prenatal SSRI exposure in animals
| Drug | Species | Dose | Administration | Exposure | Maternal Serum Monitored for Drug Conc. | 5-HT | DA | Behavior | Cardio | Health | Endpoint | Reference |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| mg/kg | ||||||||||||
| FLX, FVA | Mouse | 0–4.2 | IP | G8–G18 | Placental transfer | + | + | + | + | P20, P90 | Noorlander et al., 2008 | |
| ESC, FLX, PRX, SRT, VEN | Rat | 3–80 | OM | G12–G21 | Yes | + | ø | ø | G21–P7, P70–P100 | Capello et al., 2011 | ||
| FLX | Rat | 10 | OM | G14–P7 | No | + | + | + | P30–P120 | Forcelli and Heinrichs, 2008 | ||
| CIT | Rat | 0–20 | SC | G11–P21 | No | + | + | P22–P25 | Simpson et al., 2011 | |||
| FLX | Rat | 2.5 | OG | G6–G21 | No | + | P25 | Montero et al., 1990 | ||||
| FLX | Rat | 10 | SC | G13–G20 | No | + | P26, P70 | Cabrera-Vera et al., 1997 | ||||
| FLX | Rat | 10 | SC | G13–G20 | No | + | P26 | Cabrera-Vera and Battaglia 1998 | ||||
| ZIM | Rat | 5 | SC | G10–G20 | No | ø | +, ø | P20–P90 | Grimm and Frieder, 1987 | |||
| FLX | Rat | 12.5 | OG | G8–G20 | No | ø | ø | ø | P20 | Stewart et al., 1998 | ||
| FLX | Rat | 8, 12 | DW | G6–G20 | No | + | + | P18–P56 | Bairy et al., 2007 | |||
| FLX | Mouse | 5, 10 | SC | G13–G20 | No | + | + | P1–P120 | Cagiano et al., 2008 | |||
| FLX | Guinea pig | 7 | OM | G1–G54 | No | + | ø | P63 | Vartazarmian et al., 2005 | |||
| FLX | Mouse | 7.5 | OG | G0–P21 | No | + | ø | P40, P70 | Lisboa et al., 2007 | |||
| FLX | Mouse | 7.5 | OG | G0–P20 | No | + | P90 | Gouvêa et al. 2008 | ||||
| FLX | Rat | 10 | IP | G13–G21 | No | + | P56 | Singh et al., 1998 | ||||
| FLX | Sheep | 0.099 | IV | G120–G128 | Yes | + | G128 | Morrison et al., 2001 | ||||
| FLX | Mouse | 7.5 | OG | G0–P21 | No | +, ø | + | P40 | Favaro et al., 2008 | |||
| PRX | Mouse | 30 | Chow | G14–G16.5 | Yes | +, ø | P13–P90 | Coleman et al., 1999 | ||||
| FLX | Sheep | 0.099 | IV | G120–-G128 | Yes | ø | ø | G128 | Morrison et al., 2005 | |||
| PRX | Mouse | 30 | Chow | G14–P0 | No | ø | P34–P105 | Christensen et al., 2000 | ||||
| FLX | Rat | 10 | OG | G11–G21 | No | + | + | G21–P3 | Fornaro et al., 2007 | |||
| FLX, VEN | Rat | 8–80 | OG | G15–G20 | No | + | P1 | da-Silva et al.1999 | ||||
| FLX | Sheep | 0.099 | IV | G120–G128 | Yes | + | G128 | Morrison et al., 2004 | ||||
| FLX | Mouse | 10 | DW | G0–G21 | No | + | G14, G21 | Bauer et al., 2010 | ||||
| FLX | Rat | 10 | IP | G0–BF | No | + | P3–P30 | Periera et al., 2007 | ||||
| PRX | Rat | 10 | DW | G14–G21 | No | + | P0 | Van den Hove et al., 2008 | ||||
| FLX | Rat | 10 | IP | G9–G11 | No | ø | G21 | Swerts et al., 2010 | ||||
| FLX | Rat/rabbit | 0–15 | OG | G6–G15 | No | ø | G20/G28 | Byrd and Markham, 1994 |
+, Positive association; ø, null association; BF, breast feeding; CIT, citalopram; DW, drinking water; ESC, escitalopram; FLX, fluoxetine; FVA, fluvoxamine; G, gestation day; IV, intravenous; IP, intraperitoneal; OG, oral gavage; OM, subcutaneous osmotic minipump; P, postnatal day; SC, subcutaneous; SRT, sertraline; VEN, venlafaxine; ZIM, zimelidine.